nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—JUN—sarcoma	0.649	1	CbGaD
Irbesartan—PTGS1—Etoposide—sarcoma	0.0276	0.197	CbGbCtD
Irbesartan—CYP1A2—Dacarbazine—sarcoma	0.0252	0.18	CbGbCtD
Irbesartan—CYP3A4—Thiotepa—sarcoma	0.0238	0.17	CbGbCtD
Irbesartan—CYP2C8—Etoposide—sarcoma	0.0159	0.114	CbGbCtD
Irbesartan—CYP1A2—Etoposide—sarcoma	0.0123	0.0881	CbGbCtD
Irbesartan—CYP3A4—Mitoxantrone—sarcoma	0.0103	0.0732	CbGbCtD
Irbesartan—CYP3A4—Vincristine—sarcoma	0.00706	0.0504	CbGbCtD
Irbesartan—CYP2D6—Doxorubicin—sarcoma	0.00694	0.0495	CbGbCtD
Irbesartan—CYP3A4—Etoposide—sarcoma	0.00647	0.0462	CbGbCtD
Irbesartan—JUN—periosteum—sarcoma	0.00541	0.124	CbGeAlD
Irbesartan—CYP3A4—Doxorubicin—sarcoma	0.00441	0.0315	CbGbCtD
Irbesartan—JUN—endothelium—sarcoma	0.00199	0.0457	CbGeAlD
Irbesartan—EDNRA—mammary gland—sarcoma	0.00176	0.0404	CbGeAlD
Irbesartan—JUN—mammary gland—sarcoma	0.00161	0.0368	CbGeAlD
Irbesartan—AGTR1—endothelium—sarcoma	0.0015	0.0344	CbGeAlD
Irbesartan—EDNRA—myometrium—sarcoma	0.00125	0.0286	CbGeAlD
Irbesartan—JUN—myometrium—sarcoma	0.00114	0.0261	CbGeAlD
Irbesartan—EDNRA—seminal vesicle—sarcoma	0.00113	0.0259	CbGeAlD
Irbesartan—JUN—embryo—sarcoma	0.0011	0.0251	CbGeAlD
Irbesartan—JUN—seminal vesicle—sarcoma	0.00103	0.0236	CbGeAlD
Irbesartan—JUN—hematopoietic system—sarcoma	0.000979	0.0224	CbGeAlD
Irbesartan—JUN—connective tissue—sarcoma	0.000942	0.0216	CbGeAlD
Irbesartan—UGT1A3—liver—sarcoma	0.000896	0.0205	CbGeAlD
Irbesartan—JUN—smooth muscle tissue—sarcoma	0.000862	0.0198	CbGeAlD
Irbesartan—AGTR1—myometrium—sarcoma	0.000858	0.0197	CbGeAlD
Irbesartan—JUN—skin of body—sarcoma	0.000851	0.0195	CbGeAlD
Irbesartan—EDNRA—cardiac atrium—sarcoma	0.000814	0.0187	CbGeAlD
Irbesartan—EDNRA—uterus—sarcoma	0.00081	0.0186	CbGeAlD
Irbesartan—JUN—cardiac atrium—sarcoma	0.000743	0.017	CbGeAlD
Irbesartan—JUN—uterus—sarcoma	0.000739	0.017	CbGeAlD
Irbesartan—AGTR1—hematopoietic system—sarcoma	0.000737	0.0169	CbGeAlD
Irbesartan—EDNRA—tendon—sarcoma	0.00071	0.0163	CbGeAlD
Irbesartan—AGTR1—connective tissue—sarcoma	0.000709	0.0163	CbGeAlD
Irbesartan—JUN—lymphoid tissue—sarcoma	0.000689	0.0158	CbGeAlD
Irbesartan—PTGS1—endothelium—sarcoma	0.00066	0.0151	CbGeAlD
Irbesartan—CYP2C8—mammary gland—sarcoma	0.000656	0.015	CbGeAlD
Irbesartan—AGTR1—smooth muscle tissue—sarcoma	0.000649	0.0149	CbGeAlD
Irbesartan—JUN—tendon—sarcoma	0.000648	0.0149	CbGeAlD
Irbesartan—JUN—bone marrow—sarcoma	0.000627	0.0144	CbGeAlD
Irbesartan—EDNRA—testis—sarcoma	0.000588	0.0135	CbGeAlD
Irbesartan—CYP2C9—mammary gland—sarcoma	0.000582	0.0134	CbGeAlD
Irbesartan—AGTR1—cardiac atrium—sarcoma	0.00056	0.0128	CbGeAlD
Irbesartan—JUN—testis—sarcoma	0.000536	0.0123	CbGeAlD
Irbesartan—AGTR1—lymphoid tissue—sarcoma	0.000519	0.0119	CbGeAlD
Irbesartan—JUN—liver—sarcoma	0.000507	0.0116	CbGeAlD
Irbesartan—AGTR1—tendon—sarcoma	0.000488	0.0112	CbGeAlD
Irbesartan—EDNRA—lymph node—sarcoma	0.000426	0.00977	CbGeAlD
Irbesartan—AGTR1—testis—sarcoma	0.000404	0.00926	CbGeAlD
Irbesartan—CYP2C8—hematopoietic system—sarcoma	0.000399	0.00916	CbGeAlD
Irbesartan—JUN—lymph node—sarcoma	0.000389	0.00891	CbGeAlD
Irbesartan—AGTR1—liver—sarcoma	0.000382	0.00875	CbGeAlD
Irbesartan—CYP1A2—hematopoietic system—sarcoma	0.000374	0.00857	CbGeAlD
Irbesartan—CYP2C9—hematopoietic system—sarcoma	0.000355	0.00814	CbGeAlD
Irbesartan—PTGS1—seminal vesicle—sarcoma	0.000341	0.00782	CbGeAlD
Irbesartan—PTGS1—hematopoietic system—sarcoma	0.000324	0.00743	CbGeAlD
Irbesartan—PTGS1—connective tissue—sarcoma	0.000312	0.00715	CbGeAlD
Irbesartan—AGTR1—lymph node—sarcoma	0.000293	0.00671	CbGeAlD
Irbesartan—PTGS1—smooth muscle tissue—sarcoma	0.000285	0.00654	CbGeAlD
Irbesartan—PTGS1—skin of body—sarcoma	0.000282	0.00646	CbGeAlD
Irbesartan—CYP3A4—hematopoietic system—sarcoma	0.000271	0.00621	CbGeAlD
Irbesartan—CYP2D6—hematopoietic system—sarcoma	0.000266	0.00611	CbGeAlD
Irbesartan—PTGS1—cardiac atrium—sarcoma	0.000246	0.00564	CbGeAlD
Irbesartan—PTGS1—uterus—sarcoma	0.000245	0.00561	CbGeAlD
Irbesartan—CYP2C8—testis—sarcoma	0.000219	0.00502	CbGeAlD
Irbesartan—PTGS1—tendon—sarcoma	0.000214	0.00492	CbGeAlD
Irbesartan—CYP2C8—liver—sarcoma	0.000207	0.00475	CbGeAlD
Irbesartan—CYP1A2—liver—sarcoma	0.000194	0.00444	CbGeAlD
Irbesartan—CYP2C9—liver—sarcoma	0.000184	0.00422	CbGeAlD
Irbesartan—PTGS1—testis—sarcoma	0.000178	0.00407	CbGeAlD
Irbesartan—CYP2D6—testis—sarcoma	0.000146	0.00335	CbGeAlD
Irbesartan—CYP3A4—liver—sarcoma	0.00014	0.00321	CbGeAlD
Irbesartan—CYP2D6—liver—sarcoma	0.000138	0.00316	CbGeAlD
Irbesartan—PTGS1—lymph node—sarcoma	0.000129	0.00295	CbGeAlD
Irbesartan—Urticaria—Mitoxantrone—sarcoma	0.000113	0.00122	CcSEcCtD
Irbesartan—Breast disorder—Doxorubicin—sarcoma	0.000113	0.00122	CcSEcCtD
Irbesartan—Anorexia—Etoposide—sarcoma	0.000113	0.00122	CcSEcCtD
Irbesartan—Diarrhoea—Thiotepa—sarcoma	0.000113	0.00122	CcSEcCtD
Irbesartan—Abdominal pain—Mitoxantrone—sarcoma	0.000113	0.00122	CcSEcCtD
Irbesartan—Body temperature increased—Mitoxantrone—sarcoma	0.000113	0.00122	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000113	0.00122	CcSEcCtD
Irbesartan—Diarrhoea—Dactinomycin—sarcoma	0.000112	0.00121	CcSEcCtD
Irbesartan—Nasopharyngitis—Doxorubicin—sarcoma	0.000112	0.00121	CcSEcCtD
Irbesartan—Hypotension—Etoposide—sarcoma	0.000111	0.0012	CcSEcCtD
Irbesartan—Muscular weakness—Doxorubicin—sarcoma	0.00011	0.00119	CcSEcCtD
Irbesartan—Neutropenia—Epirubicin—sarcoma	0.000109	0.00118	CcSEcCtD
Irbesartan—Dizziness—Thiotepa—sarcoma	0.000109	0.00118	CcSEcCtD
Irbesartan—Abdominal distension—Doxorubicin—sarcoma	0.000109	0.00118	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Epirubicin—sarcoma	0.000109	0.00117	CcSEcCtD
Irbesartan—Influenza—Doxorubicin—sarcoma	0.000108	0.00117	CcSEcCtD
Irbesartan—Asthma—Doxorubicin—sarcoma	0.000108	0.00117	CcSEcCtD
Irbesartan—Dysphagia—Doxorubicin—sarcoma	0.000108	0.00117	CcSEcCtD
Irbesartan—Hypersensitivity—Vincristine—sarcoma	0.000108	0.00117	CcSEcCtD
Irbesartan—Photosensitivity reaction—Epirubicin—sarcoma	0.000107	0.00115	CcSEcCtD
Irbesartan—Paraesthesia—Etoposide—sarcoma	0.000106	0.00115	CcSEcCtD
Irbesartan—Weight increased—Epirubicin—sarcoma	0.000106	0.00115	CcSEcCtD
Irbesartan—Pancreatitis—Doxorubicin—sarcoma	0.000106	0.00115	CcSEcCtD
Irbesartan—Dyspnoea—Etoposide—sarcoma	0.000106	0.00114	CcSEcCtD
Irbesartan—Hyperglycaemia—Epirubicin—sarcoma	0.000105	0.00114	CcSEcCtD
Irbesartan—Somnolence—Etoposide—sarcoma	0.000105	0.00114	CcSEcCtD
Irbesartan—Angina pectoris—Doxorubicin—sarcoma	0.000105	0.00114	CcSEcCtD
Irbesartan—Hypersensitivity—Mitoxantrone—sarcoma	0.000105	0.00114	CcSEcCtD
Irbesartan—Asthenia—Vincristine—sarcoma	0.000105	0.00114	CcSEcCtD
Irbesartan—Vomiting—Thiotepa—sarcoma	0.000105	0.00113	CcSEcCtD
Irbesartan—Pneumonia—Epirubicin—sarcoma	0.000105	0.00113	CcSEcCtD
Irbesartan—Vomiting—Dactinomycin—sarcoma	0.000104	0.00113	CcSEcCtD
Irbesartan—Rash—Thiotepa—sarcoma	0.000104	0.00113	CcSEcCtD
Irbesartan—Dermatitis—Thiotepa—sarcoma	0.000104	0.00112	CcSEcCtD
Irbesartan—Headache—Thiotepa—sarcoma	0.000103	0.00112	CcSEcCtD
Irbesartan—Rash—Dactinomycin—sarcoma	0.000103	0.00112	CcSEcCtD
Irbesartan—Decreased appetite—Etoposide—sarcoma	0.000103	0.00111	CcSEcCtD
Irbesartan—Renal failure—Epirubicin—sarcoma	0.000102	0.00111	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Etoposide—sarcoma	0.000102	0.00111	CcSEcCtD
Irbesartan—Asthenia—Mitoxantrone—sarcoma	0.000102	0.00111	CcSEcCtD
Irbesartan—Fatigue—Etoposide—sarcoma	0.000102	0.00111	CcSEcCtD
Irbesartan—Jaundice—Epirubicin—sarcoma	0.000101	0.0011	CcSEcCtD
Irbesartan—Pain—Etoposide—sarcoma	0.000101	0.0011	CcSEcCtD
Irbesartan—Constipation—Etoposide—sarcoma	0.000101	0.0011	CcSEcCtD
Irbesartan—Urinary tract infection—Epirubicin—sarcoma	0.000101	0.0011	CcSEcCtD
Irbesartan—Conjunctivitis—Epirubicin—sarcoma	0.000101	0.0011	CcSEcCtD
Irbesartan—Neutropenia—Doxorubicin—sarcoma	0.000101	0.00109	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Doxorubicin—sarcoma	0.0001	0.00109	CcSEcCtD
Irbesartan—Diarrhoea—Vincristine—sarcoma	0.0001	0.00108	CcSEcCtD
Irbesartan—Photosensitivity reaction—Doxorubicin—sarcoma	9.86e-05	0.00107	CcSEcCtD
Irbesartan—Hepatobiliary disease—Epirubicin—sarcoma	9.85e-05	0.00107	CcSEcCtD
Irbesartan—Weight increased—Doxorubicin—sarcoma	9.83e-05	0.00106	CcSEcCtD
Irbesartan—Epistaxis—Epirubicin—sarcoma	9.82e-05	0.00106	CcSEcCtD
Irbesartan—Nausea—Thiotepa—sarcoma	9.8e-05	0.00106	CcSEcCtD
Irbesartan—Feeling abnormal—Etoposide—sarcoma	9.76e-05	0.00106	CcSEcCtD
Irbesartan—Hyperglycaemia—Doxorubicin—sarcoma	9.75e-05	0.00105	CcSEcCtD
Irbesartan—Diarrhoea—Mitoxantrone—sarcoma	9.75e-05	0.00105	CcSEcCtD
Irbesartan—Nausea—Dactinomycin—sarcoma	9.72e-05	0.00105	CcSEcCtD
Irbesartan—Agranulocytosis—Epirubicin—sarcoma	9.72e-05	0.00105	CcSEcCtD
Irbesartan—Pneumonia—Doxorubicin—sarcoma	9.69e-05	0.00105	CcSEcCtD
Irbesartan—Gastrointestinal pain—Etoposide—sarcoma	9.69e-05	0.00105	CcSEcCtD
Irbesartan—Dizziness—Vincristine—sarcoma	9.67e-05	0.00105	CcSEcCtD
Irbesartan—Bradycardia—Epirubicin—sarcoma	9.52e-05	0.00103	CcSEcCtD
Irbesartan—Renal failure—Doxorubicin—sarcoma	9.47e-05	0.00102	CcSEcCtD
Irbesartan—Urticaria—Etoposide—sarcoma	9.41e-05	0.00102	CcSEcCtD
Irbesartan—Jaundice—Doxorubicin—sarcoma	9.39e-05	0.00102	CcSEcCtD
Irbesartan—Rhinitis—Epirubicin—sarcoma	9.37e-05	0.00101	CcSEcCtD
Irbesartan—Abdominal pain—Etoposide—sarcoma	9.37e-05	0.00101	CcSEcCtD
Irbesartan—Body temperature increased—Etoposide—sarcoma	9.37e-05	0.00101	CcSEcCtD
Irbesartan—Conjunctivitis—Doxorubicin—sarcoma	9.37e-05	0.00101	CcSEcCtD
Irbesartan—Urinary tract infection—Doxorubicin—sarcoma	9.37e-05	0.00101	CcSEcCtD
Irbesartan—Hepatitis—Epirubicin—sarcoma	9.35e-05	0.00101	CcSEcCtD
Irbesartan—Hypoaesthesia—Epirubicin—sarcoma	9.3e-05	0.00101	CcSEcCtD
Irbesartan—Vomiting—Vincristine—sarcoma	9.3e-05	0.00101	CcSEcCtD
Irbesartan—Pharyngitis—Epirubicin—sarcoma	9.28e-05	0.001	CcSEcCtD
Irbesartan—Urinary tract disorder—Epirubicin—sarcoma	9.23e-05	0.000999	CcSEcCtD
Irbesartan—Rash—Vincristine—sarcoma	9.22e-05	0.000998	CcSEcCtD
Irbesartan—Dermatitis—Vincristine—sarcoma	9.21e-05	0.000997	CcSEcCtD
Irbesartan—Oedema peripheral—Epirubicin—sarcoma	9.21e-05	0.000996	CcSEcCtD
Irbesartan—Connective tissue disorder—Epirubicin—sarcoma	9.19e-05	0.000994	CcSEcCtD
Irbesartan—Urethral disorder—Epirubicin—sarcoma	9.16e-05	0.000992	CcSEcCtD
Irbesartan—Headache—Vincristine—sarcoma	9.16e-05	0.000991	CcSEcCtD
Irbesartan—Hepatobiliary disease—Doxorubicin—sarcoma	9.11e-05	0.000986	CcSEcCtD
Irbesartan—Epistaxis—Doxorubicin—sarcoma	9.09e-05	0.000983	CcSEcCtD
Irbesartan—Vomiting—Mitoxantrone—sarcoma	9.06e-05	0.00098	CcSEcCtD
Irbesartan—Visual impairment—Epirubicin—sarcoma	9.01e-05	0.000975	CcSEcCtD
Irbesartan—Agranulocytosis—Doxorubicin—sarcoma	8.99e-05	0.000973	CcSEcCtD
Irbesartan—Rash—Mitoxantrone—sarcoma	8.98e-05	0.000972	CcSEcCtD
Irbesartan—Dermatitis—Mitoxantrone—sarcoma	8.97e-05	0.000971	CcSEcCtD
Irbesartan—Headache—Mitoxantrone—sarcoma	8.92e-05	0.000966	CcSEcCtD
Irbesartan—Bradycardia—Doxorubicin—sarcoma	8.81e-05	0.000953	CcSEcCtD
Irbesartan—Hypersensitivity—Etoposide—sarcoma	8.73e-05	0.000945	CcSEcCtD
Irbesartan—Tinnitus—Epirubicin—sarcoma	8.72e-05	0.000943	CcSEcCtD
Irbesartan—Nausea—Vincristine—sarcoma	8.69e-05	0.00094	CcSEcCtD
Irbesartan—Flushing—Epirubicin—sarcoma	8.68e-05	0.000939	CcSEcCtD
Irbesartan—Cardiac disorder—Epirubicin—sarcoma	8.68e-05	0.000939	CcSEcCtD
Irbesartan—Rhinitis—Doxorubicin—sarcoma	8.67e-05	0.000938	CcSEcCtD
Irbesartan—Hepatitis—Doxorubicin—sarcoma	8.65e-05	0.000936	CcSEcCtD
Irbesartan—Hypoaesthesia—Doxorubicin—sarcoma	8.61e-05	0.000931	CcSEcCtD
Irbesartan—Pharyngitis—Doxorubicin—sarcoma	8.58e-05	0.000929	CcSEcCtD
Irbesartan—Urinary tract disorder—Doxorubicin—sarcoma	8.54e-05	0.000924	CcSEcCtD
Irbesartan—Oedema peripheral—Doxorubicin—sarcoma	8.52e-05	0.000922	CcSEcCtD
Irbesartan—Asthenia—Etoposide—sarcoma	8.5e-05	0.00092	CcSEcCtD
Irbesartan—Connective tissue disorder—Doxorubicin—sarcoma	8.5e-05	0.00092	CcSEcCtD
Irbesartan—Angiopathy—Epirubicin—sarcoma	8.48e-05	0.000918	CcSEcCtD
Irbesartan—Urethral disorder—Doxorubicin—sarcoma	8.48e-05	0.000917	CcSEcCtD
Irbesartan—Nausea—Mitoxantrone—sarcoma	8.46e-05	0.000916	CcSEcCtD
Irbesartan—Immune system disorder—Epirubicin—sarcoma	8.44e-05	0.000914	CcSEcCtD
Irbesartan—Mediastinal disorder—Epirubicin—sarcoma	8.42e-05	0.000912	CcSEcCtD
Irbesartan—Chills—Epirubicin—sarcoma	8.39e-05	0.000908	CcSEcCtD
Irbesartan—Pruritus—Etoposide—sarcoma	8.38e-05	0.000907	CcSEcCtD
Irbesartan—Arrhythmia—Epirubicin—sarcoma	8.35e-05	0.000904	CcSEcCtD
Irbesartan—Visual impairment—Doxorubicin—sarcoma	8.34e-05	0.000902	CcSEcCtD
Irbesartan—Malnutrition—Epirubicin—sarcoma	8.14e-05	0.000881	CcSEcCtD
Irbesartan—Erythema—Epirubicin—sarcoma	8.14e-05	0.000881	CcSEcCtD
Irbesartan—Diarrhoea—Etoposide—sarcoma	8.11e-05	0.000877	CcSEcCtD
Irbesartan—Tinnitus—Doxorubicin—sarcoma	8.06e-05	0.000873	CcSEcCtD
Irbesartan—Cardiac disorder—Doxorubicin—sarcoma	8.03e-05	0.000869	CcSEcCtD
Irbesartan—Flushing—Doxorubicin—sarcoma	8.03e-05	0.000869	CcSEcCtD
Irbesartan—Flatulence—Epirubicin—sarcoma	8.02e-05	0.000868	CcSEcCtD
Irbesartan—Tension—Epirubicin—sarcoma	7.99e-05	0.000864	CcSEcCtD
Irbesartan—Dysgeusia—Epirubicin—sarcoma	7.97e-05	0.000862	CcSEcCtD
Irbesartan—Nervousness—Epirubicin—sarcoma	7.9e-05	0.000855	CcSEcCtD
Irbesartan—Angiopathy—Doxorubicin—sarcoma	7.85e-05	0.000849	CcSEcCtD
Irbesartan—Dizziness—Etoposide—sarcoma	7.83e-05	0.000848	CcSEcCtD
Irbesartan—Muscle spasms—Epirubicin—sarcoma	7.82e-05	0.000847	CcSEcCtD
Irbesartan—Immune system disorder—Doxorubicin—sarcoma	7.81e-05	0.000845	CcSEcCtD
Irbesartan—Mediastinal disorder—Doxorubicin—sarcoma	7.79e-05	0.000844	CcSEcCtD
Irbesartan—Chills—Doxorubicin—sarcoma	7.76e-05	0.00084	CcSEcCtD
Irbesartan—Arrhythmia—Doxorubicin—sarcoma	7.73e-05	0.000836	CcSEcCtD
Irbesartan—Vision blurred—Epirubicin—sarcoma	7.67e-05	0.00083	CcSEcCtD
Irbesartan—Ill-defined disorder—Epirubicin—sarcoma	7.55e-05	0.000817	CcSEcCtD
Irbesartan—Vomiting—Etoposide—sarcoma	7.53e-05	0.000815	CcSEcCtD
Irbesartan—Erythema—Doxorubicin—sarcoma	7.53e-05	0.000815	CcSEcCtD
Irbesartan—Malnutrition—Doxorubicin—sarcoma	7.53e-05	0.000815	CcSEcCtD
Irbesartan—Anaemia—Epirubicin—sarcoma	7.52e-05	0.000814	CcSEcCtD
Irbesartan—Agitation—Epirubicin—sarcoma	7.48e-05	0.000809	CcSEcCtD
Irbesartan—Rash—Etoposide—sarcoma	7.47e-05	0.000808	CcSEcCtD
Irbesartan—Dermatitis—Etoposide—sarcoma	7.46e-05	0.000808	CcSEcCtD
Irbesartan—Headache—Etoposide—sarcoma	7.42e-05	0.000803	CcSEcCtD
Irbesartan—Flatulence—Doxorubicin—sarcoma	7.42e-05	0.000803	CcSEcCtD
Irbesartan—Tension—Doxorubicin—sarcoma	7.39e-05	0.0008	CcSEcCtD
Irbesartan—Dysgeusia—Doxorubicin—sarcoma	7.37e-05	0.000798	CcSEcCtD
Irbesartan—Malaise—Epirubicin—sarcoma	7.34e-05	0.000794	CcSEcCtD
Irbesartan—Nervousness—Doxorubicin—sarcoma	7.31e-05	0.000791	CcSEcCtD
Irbesartan—Vertigo—Epirubicin—sarcoma	7.31e-05	0.000791	CcSEcCtD
Irbesartan—Syncope—Epirubicin—sarcoma	7.3e-05	0.00079	CcSEcCtD
Irbesartan—Leukopenia—Epirubicin—sarcoma	7.28e-05	0.000788	CcSEcCtD
Irbesartan—Muscle spasms—Doxorubicin—sarcoma	7.24e-05	0.000783	CcSEcCtD
Irbesartan—JUN—TGF-beta Signaling Pathway—CCND1—sarcoma	7.17e-05	0.000959	CbGpPWpGaD
Irbesartan—Loss of consciousness—Epirubicin—sarcoma	7.15e-05	0.000774	CcSEcCtD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—sarcoma	7.13e-05	0.000953	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—CREB1—sarcoma	7.11e-05	0.00095	CbGpPWpGaD
Irbesartan—Cough—Epirubicin—sarcoma	7.1e-05	0.000768	CcSEcCtD
Irbesartan—Vision blurred—Doxorubicin—sarcoma	7.1e-05	0.000768	CcSEcCtD
Irbesartan—JUN—TNF alpha Signaling Pathway—KRAS—sarcoma	7.09e-05	0.000948	CbGpPWpGaD
Irbesartan—JUN—Wnt Signaling Pathway and Pluripotency—MYC—sarcoma	7.07e-05	0.000945	CbGpPWpGaD
Irbesartan—Nausea—Etoposide—sarcoma	7.04e-05	0.000762	CcSEcCtD
Irbesartan—Hypertension—Epirubicin—sarcoma	7.03e-05	0.00076	CcSEcCtD
Irbesartan—Ill-defined disorder—Doxorubicin—sarcoma	6.99e-05	0.000756	CcSEcCtD
Irbesartan—Anaemia—Doxorubicin—sarcoma	6.96e-05	0.000753	CcSEcCtD
Irbesartan—Myalgia—Epirubicin—sarcoma	6.93e-05	0.00075	CcSEcCtD
Irbesartan—Chest pain—Epirubicin—sarcoma	6.93e-05	0.00075	CcSEcCtD
Irbesartan—Arthralgia—Epirubicin—sarcoma	6.93e-05	0.00075	CcSEcCtD
Irbesartan—Agitation—Doxorubicin—sarcoma	6.92e-05	0.000749	CcSEcCtD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—TP53—sarcoma	6.91e-05	0.000924	CbGpPWpGaD
Irbesartan—Anxiety—Epirubicin—sarcoma	6.9e-05	0.000747	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	6.88e-05	0.000745	CcSEcCtD
Irbesartan—Discomfort—Epirubicin—sarcoma	6.84e-05	0.000741	CcSEcCtD
Irbesartan—EDNRA—GPCR downstream signaling—CXCR4—sarcoma	6.83e-05	0.000914	CbGpPWpGaD
Irbesartan—Malaise—Doxorubicin—sarcoma	6.79e-05	0.000735	CcSEcCtD
Irbesartan—JUN—Apoptosis—TP53—sarcoma	6.78e-05	0.000906	CbGpPWpGaD
Irbesartan—Dry mouth—Epirubicin—sarcoma	6.78e-05	0.000733	CcSEcCtD
Irbesartan—Vertigo—Doxorubicin—sarcoma	6.76e-05	0.000732	CcSEcCtD
Irbesartan—JUN—ErbB1 downstream signaling—EGFR—sarcoma	6.76e-05	0.000903	CbGpPWpGaD
Irbesartan—Syncope—Doxorubicin—sarcoma	6.75e-05	0.000731	CcSEcCtD
Irbesartan—JUN—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—sarcoma	6.74e-05	0.000901	CbGpPWpGaD
Irbesartan—Leukopenia—Doxorubicin—sarcoma	6.74e-05	0.000729	CcSEcCtD
Irbesartan—JUN—PDGFR-beta signaling pathway—SRC—sarcoma	6.7e-05	0.000896	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—MYC—sarcoma	6.7e-05	0.000896	CbGpPWpGaD
Irbesartan—JUN—Signaling by NOTCH—MYC—sarcoma	6.7e-05	0.000896	CbGpPWpGaD
Irbesartan—Oedema—Epirubicin—sarcoma	6.64e-05	0.000719	CcSEcCtD
Irbesartan—Anaphylactic shock—Epirubicin—sarcoma	6.64e-05	0.000719	CcSEcCtD
Irbesartan—JUN—BDNF signaling pathway—CTNNB1—sarcoma	6.62e-05	0.000885	CbGpPWpGaD
Irbesartan—Loss of consciousness—Doxorubicin—sarcoma	6.62e-05	0.000716	CcSEcCtD
Irbesartan—Infection—Epirubicin—sarcoma	6.6e-05	0.000714	CcSEcCtD
Irbesartan—Cough—Doxorubicin—sarcoma	6.57e-05	0.000711	CcSEcCtD
Irbesartan—Shock—Epirubicin—sarcoma	6.53e-05	0.000707	CcSEcCtD
Irbesartan—Nervous system disorder—Epirubicin—sarcoma	6.51e-05	0.000705	CcSEcCtD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—MDM2—sarcoma	6.51e-05	0.00087	CbGpPWpGaD
Irbesartan—Thrombocytopenia—Epirubicin—sarcoma	6.5e-05	0.000704	CcSEcCtD
Irbesartan—Hypertension—Doxorubicin—sarcoma	6.5e-05	0.000703	CcSEcCtD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—sarcoma	6.5e-05	0.000868	CbGpPWpGaD
Irbesartan—Tachycardia—Epirubicin—sarcoma	6.48e-05	0.000701	CcSEcCtD
Irbesartan—Skin disorder—Epirubicin—sarcoma	6.45e-05	0.000698	CcSEcCtD
Irbesartan—JUN—PDGFR-beta signaling pathway—NRAS—sarcoma	6.45e-05	0.000862	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—CCND1—sarcoma	6.44e-05	0.000861	CbGpPWpGaD
Irbesartan—Hyperhidrosis—Epirubicin—sarcoma	6.42e-05	0.000695	CcSEcCtD
Irbesartan—JUN—TGF-beta Signaling Pathway—SRC—sarcoma	6.42e-05	0.000858	CbGpPWpGaD
Irbesartan—Myalgia—Doxorubicin—sarcoma	6.41e-05	0.000694	CcSEcCtD
Irbesartan—Arthralgia—Doxorubicin—sarcoma	6.41e-05	0.000694	CcSEcCtD
Irbesartan—Chest pain—Doxorubicin—sarcoma	6.41e-05	0.000694	CcSEcCtD
Irbesartan—Anxiety—Doxorubicin—sarcoma	6.39e-05	0.000691	CcSEcCtD
Irbesartan—JUN—ErbB1 downstream signaling—KRAS—sarcoma	6.38e-05	0.000853	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	6.38e-05	0.000852	CbGpPWpGaD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	6.37e-05	0.000689	CcSEcCtD
Irbesartan—JUN—Apoptosis Modulation and Signaling—TP53—sarcoma	6.36e-05	0.00085	CbGpPWpGaD
Irbesartan—Discomfort—Doxorubicin—sarcoma	6.33e-05	0.000685	CcSEcCtD
Irbesartan—Anorexia—Epirubicin—sarcoma	6.33e-05	0.000685	CcSEcCtD
Irbesartan—Dry mouth—Doxorubicin—sarcoma	6.27e-05	0.000678	CcSEcCtD
Irbesartan—JUN—Cellular Senescence—MDM2—sarcoma	6.26e-05	0.000836	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—CTNNB1—sarcoma	6.21e-05	0.00083	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CXCR4—sarcoma	6.21e-05	0.00083	CbGpPWpGaD
Irbesartan—Hypotension—Epirubicin—sarcoma	6.21e-05	0.000672	CcSEcCtD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—KRAS—sarcoma	6.19e-05	0.000828	CbGpPWpGaD
Irbesartan—Anaphylactic shock—Doxorubicin—sarcoma	6.14e-05	0.000665	CcSEcCtD
Irbesartan—Oedema—Doxorubicin—sarcoma	6.14e-05	0.000665	CcSEcCtD
Irbesartan—JUN—TCR Signaling Pathway—HRAS—sarcoma	6.14e-05	0.00082	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—sarcoma	6.14e-05	0.00082	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	6.13e-05	0.000819	CbGpPWpGaD
Irbesartan—Infection—Doxorubicin—sarcoma	6.1e-05	0.000661	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Epirubicin—sarcoma	6.05e-05	0.000655	CcSEcCtD
Irbesartan—Shock—Doxorubicin—sarcoma	6.05e-05	0.000654	CcSEcCtD
Irbesartan—JUN—TNF alpha Signaling Pathway—HRAS—sarcoma	6.03e-05	0.000806	CbGpPWpGaD
Irbesartan—Nervous system disorder—Doxorubicin—sarcoma	6.03e-05	0.000652	CcSEcCtD
Irbesartan—Thrombocytopenia—Doxorubicin—sarcoma	6.02e-05	0.000651	CcSEcCtD
Irbesartan—JUN—PDGFR-beta signaling pathway—MYC—sarcoma	6.01e-05	0.000803	CbGpPWpGaD
Irbesartan—CYP1A2—Tryptophan metabolism—MDM2—sarcoma	6e-05	0.000802	CbGpPWpGaD
Irbesartan—Tachycardia—Doxorubicin—sarcoma	6e-05	0.000649	CcSEcCtD
Irbesartan—JUN—BDNF signaling pathway—SRC—sarcoma	5.99e-05	0.0008	CbGpPWpGaD
Irbesartan—Skin disorder—Doxorubicin—sarcoma	5.97e-05	0.000646	CcSEcCtD
Irbesartan—Paraesthesia—Epirubicin—sarcoma	5.96e-05	0.000645	CcSEcCtD
Irbesartan—JUN—Innate Immune System—PLCG1—sarcoma	5.94e-05	0.000794	CbGpPWpGaD
Irbesartan—Hyperhidrosis—Doxorubicin—sarcoma	5.94e-05	0.000643	CcSEcCtD
Irbesartan—Dyspnoea—Epirubicin—sarcoma	5.92e-05	0.000641	CcSEcCtD
Irbesartan—Somnolence—Epirubicin—sarcoma	5.9e-05	0.000639	CcSEcCtD
Irbesartan—Anorexia—Doxorubicin—sarcoma	5.86e-05	0.000634	CcSEcCtD
Irbesartan—Dyspepsia—Epirubicin—sarcoma	5.85e-05	0.000633	CcSEcCtD
Irbesartan—JUN—Wnt Signaling Pathway and Pluripotency—TP53—sarcoma	5.81e-05	0.000776	CbGpPWpGaD
Irbesartan—JUN—B Cell Receptor Signaling Pathway—HRAS—sarcoma	5.78e-05	0.000773	CbGpPWpGaD
Irbesartan—Decreased appetite—Epirubicin—sarcoma	5.77e-05	0.000625	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—TLE1—sarcoma	5.76e-05	0.000769	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—MYC—sarcoma	5.75e-05	0.000769	CbGpPWpGaD
Irbesartan—Hypotension—Doxorubicin—sarcoma	5.74e-05	0.000621	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Epirubicin—sarcoma	5.73e-05	0.00062	CcSEcCtD
Irbesartan—Fatigue—Epirubicin—sarcoma	5.73e-05	0.00062	CcSEcCtD
Irbesartan—Pain—Epirubicin—sarcoma	5.68e-05	0.000615	CcSEcCtD
Irbesartan—Constipation—Epirubicin—sarcoma	5.68e-05	0.000615	CcSEcCtD
Irbesartan—JUN—Senescence and Autophagy in Cancer—TP53—sarcoma	5.67e-05	0.000758	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—ATF1—sarcoma	5.64e-05	0.000754	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—VEGFA—sarcoma	5.61e-05	0.00075	CbGpPWpGaD
Irbesartan—Musculoskeletal discomfort—Doxorubicin—sarcoma	5.6e-05	0.000606	CcSEcCtD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—sarcoma	5.59e-05	0.000748	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—KRAS—sarcoma	5.55e-05	0.000742	CbGpPWpGaD
Irbesartan—Paraesthesia—Doxorubicin—sarcoma	5.52e-05	0.000597	CcSEcCtD
Irbesartan—JUN—Signaling by NOTCH—TP53—sarcoma	5.51e-05	0.000736	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—TP53—sarcoma	5.51e-05	0.000736	CbGpPWpGaD
Irbesartan—Dyspnoea—Doxorubicin—sarcoma	5.48e-05	0.000593	CcSEcCtD
Irbesartan—Feeling abnormal—Epirubicin—sarcoma	5.47e-05	0.000592	CcSEcCtD
Irbesartan—JUN—SIDS Susceptibility Pathways—VEGFA—sarcoma	5.47e-05	0.000731	CbGpPWpGaD
Irbesartan—Somnolence—Doxorubicin—sarcoma	5.46e-05	0.000591	CcSEcCtD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—SRC—sarcoma	5.45e-05	0.000728	CbGpPWpGaD
Irbesartan—Gastrointestinal pain—Epirubicin—sarcoma	5.43e-05	0.000588	CcSEcCtD
Irbesartan—JUN—ErbB1 downstream signaling—HRAS—sarcoma	5.43e-05	0.000725	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—HRAS—sarcoma	5.43e-05	0.000725	CbGpPWpGaD
Irbesartan—Dyspepsia—Doxorubicin—sarcoma	5.41e-05	0.000585	CcSEcCtD
Irbesartan—JUN—Direct p53 effectors—EGFR—sarcoma	5.37e-05	0.000717	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CXCR4—sarcoma	5.36e-05	0.000717	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	5.36e-05	0.000717	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—CCND1—sarcoma	5.36e-05	0.000716	CbGpPWpGaD
Irbesartan—Decreased appetite—Doxorubicin—sarcoma	5.34e-05	0.000578	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	5.34e-05	0.000713	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—CTNNB1—sarcoma	5.31e-05	0.000709	CbGpPWpGaD
Irbesartan—Gastrointestinal disorder—Doxorubicin—sarcoma	5.31e-05	0.000574	CcSEcCtD
Irbesartan—Fatigue—Doxorubicin—sarcoma	5.3e-05	0.000573	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	5.28e-05	0.000706	CbGpPWpGaD
Irbesartan—Urticaria—Epirubicin—sarcoma	5.28e-05	0.000571	CcSEcCtD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—HRAS—sarcoma	5.27e-05	0.000704	CbGpPWpGaD
Irbesartan—Pain—Doxorubicin—sarcoma	5.25e-05	0.000569	CcSEcCtD
Irbesartan—Constipation—Doxorubicin—sarcoma	5.25e-05	0.000569	CcSEcCtD
Irbesartan—Body temperature increased—Epirubicin—sarcoma	5.25e-05	0.000568	CcSEcCtD
Irbesartan—Abdominal pain—Epirubicin—sarcoma	5.25e-05	0.000568	CcSEcCtD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—sarcoma	5.22e-05	0.000697	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	5.22e-05	0.000697	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—MYC—sarcoma	5.17e-05	0.00069	CbGpPWpGaD
Irbesartan—JUN—Oxidative Stress Induced Senescence—TP53—sarcoma	5.13e-05	0.000686	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—sarcoma	5.1e-05	0.000681	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—NRAS—sarcoma	5.09e-05	0.000681	CbGpPWpGaD
Irbesartan—Feeling abnormal—Doxorubicin—sarcoma	5.06e-05	0.000548	CcSEcCtD
Irbesartan—JUN—Integrated Breast Cancer Pathway—EGFR—sarcoma	5.05e-05	0.000675	CbGpPWpGaD
Irbesartan—Gastrointestinal pain—Doxorubicin—sarcoma	5.02e-05	0.000544	CcSEcCtD
Irbesartan—Hypersensitivity—Epirubicin—sarcoma	4.89e-05	0.000529	CcSEcCtD
Irbesartan—JUN—Immune System—CD34—sarcoma	4.89e-05	0.000654	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—NRAS—sarcoma	4.88e-05	0.000653	CbGpPWpGaD
Irbesartan—Urticaria—Doxorubicin—sarcoma	4.88e-05	0.000528	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—CXCR4—sarcoma	4.87e-05	0.000651	CbGpPWpGaD
Irbesartan—Body temperature increased—Doxorubicin—sarcoma	4.86e-05	0.000526	CcSEcCtD
Irbesartan—Abdominal pain—Doxorubicin—sarcoma	4.86e-05	0.000526	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—VEGFC—sarcoma	4.86e-05	0.000649	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—sarcoma	4.82e-05	0.000644	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—SRC—sarcoma	4.8e-05	0.000641	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	4.78e-05	0.000638	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—EGFR—sarcoma	4.78e-05	0.000638	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—KRAS—sarcoma	4.77e-05	0.000638	CbGpPWpGaD
Irbesartan—Asthenia—Epirubicin—sarcoma	4.76e-05	0.000516	CcSEcCtD
Irbesartan—JUN—MAPK Signaling Pathway—MYC—sarcoma	4.74e-05	0.000634	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—MDM2—sarcoma	4.73e-05	0.000632	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—TP53—sarcoma	4.72e-05	0.000631	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—HRAS—sarcoma	4.72e-05	0.000631	CbGpPWpGaD
Irbesartan—Pruritus—Epirubicin—sarcoma	4.7e-05	0.000508	CcSEcCtD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	4.68e-05	0.000625	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—SRC—sarcoma	4.68e-05	0.000625	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—VEGFA—sarcoma	4.67e-05	0.000624	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	4.65e-05	0.000622	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—EGFR—sarcoma	4.64e-05	0.00062	CbGpPWpGaD
Irbesartan—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	4.63e-05	0.000619	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	4.56e-05	0.000609	CbGpPWpGaD
Irbesartan—Diarrhoea—Epirubicin—sarcoma	4.54e-05	0.000492	CcSEcCtD
Irbesartan—Hypersensitivity—Doxorubicin—sarcoma	4.53e-05	0.00049	CcSEcCtD
Irbesartan—AGTR1—Signaling Pathways—TLE1—sarcoma	4.52e-05	0.000604	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—KRAS—sarcoma	4.51e-05	0.000603	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—TP53—sarcoma	4.51e-05	0.000602	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	4.5e-05	0.000602	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—EGFR—sarcoma	4.45e-05	0.000595	CbGpPWpGaD
Irbesartan—Asthenia—Doxorubicin—sarcoma	4.41e-05	0.000477	CcSEcCtD
Irbesartan—Dizziness—Epirubicin—sarcoma	4.39e-05	0.000475	CcSEcCtD
Irbesartan—JUN—MAPK Signaling Pathway—KRAS—sarcoma	4.38e-05	0.000586	CbGpPWpGaD
Irbesartan—Pruritus—Doxorubicin—sarcoma	4.35e-05	0.00047	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	4.28e-05	0.000572	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—TP53—sarcoma	4.24e-05	0.000567	CbGpPWpGaD
Irbesartan—Vomiting—Epirubicin—sarcoma	4.22e-05	0.000457	CcSEcCtD
Irbesartan—JUN—Innate Immune System—FOXO1—sarcoma	4.22e-05	0.000563	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—HRAS—sarcoma	4.21e-05	0.000563	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—PDGFRB—sarcoma	4.21e-05	0.000562	CbGpPWpGaD
Irbesartan—Diarrhoea—Doxorubicin—sarcoma	4.2e-05	0.000455	CcSEcCtD
Irbesartan—JUN—Focal Adhesion—EGFR—sarcoma	4.2e-05	0.000562	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—KRAS—sarcoma	4.2e-05	0.000562	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—MYC—sarcoma	4.19e-05	0.00056	CbGpPWpGaD
Irbesartan—Rash—Epirubicin—sarcoma	4.19e-05	0.000453	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	4.19e-05	0.00056	CbGpPWpGaD
Irbesartan—Dermatitis—Epirubicin—sarcoma	4.18e-05	0.000453	CcSEcCtD
Irbesartan—Headache—Epirubicin—sarcoma	4.16e-05	0.00045	CcSEcCtD
Irbesartan—JUN—Innate Immune System—PDGFRA—sarcoma	4.14e-05	0.000554	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	4.1e-05	0.000548	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	4.1e-05	0.000548	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—sarcoma	4.09e-05	0.000547	CbGpPWpGaD
Irbesartan—Dizziness—Doxorubicin—sarcoma	4.06e-05	0.00044	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	3.95e-05	0.000529	CbGpPWpGaD
Irbesartan—Nausea—Epirubicin—sarcoma	3.94e-05	0.000427	CcSEcCtD
Irbesartan—UGT1A3—Metabolism—ENO2—sarcoma	3.91e-05	0.000522	CbGpPWpGaD
Irbesartan—Vomiting—Doxorubicin—sarcoma	3.91e-05	0.000423	CcSEcCtD
Irbesartan—JUN—MAPK Signaling Pathway—TP53—sarcoma	3.89e-05	0.000521	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—HBA1—sarcoma	3.88e-05	0.000519	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—FLT1—sarcoma	3.88e-05	0.000519	CbGpPWpGaD
Irbesartan—Rash—Doxorubicin—sarcoma	3.87e-05	0.000419	CcSEcCtD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	3.87e-05	0.000518	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—HRAS—sarcoma	3.87e-05	0.000518	CbGpPWpGaD
Irbesartan—Dermatitis—Doxorubicin—sarcoma	3.87e-05	0.000419	CcSEcCtD
Irbesartan—Headache—Doxorubicin—sarcoma	3.85e-05	0.000417	CcSEcCtD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—HRAS—sarcoma	3.83e-05	0.000513	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PLCG1—sarcoma	3.82e-05	0.00051	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFC—sarcoma	3.81e-05	0.000509	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CXCR4—sarcoma	3.67e-05	0.00049	CbGpPWpGaD
Irbesartan—Nausea—Doxorubicin—sarcoma	3.65e-05	0.000395	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—ATF1—sarcoma	3.63e-05	0.000485	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—VEGFA—sarcoma	3.59e-05	0.00048	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—TP53—sarcoma	3.59e-05	0.00048	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	3.57e-05	0.000478	CbGpPWpGaD
Irbesartan—JUN—Immune System—PTPRC—sarcoma	3.54e-05	0.000473	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	3.51e-05	0.00047	CbGpPWpGaD
Irbesartan—JUN—Immune System—PLCG1—sarcoma	3.46e-05	0.000463	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—HRAS—sarcoma	3.38e-05	0.000451	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TLE1—sarcoma	3.37e-05	0.000451	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—TP53—sarcoma	3.37e-05	0.000451	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CREB1—sarcoma	3.32e-05	0.000444	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PLCG1—sarcoma	3.32e-05	0.000443	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	3.29e-05	0.00044	CbGpPWpGaD
Irbesartan—JUN—Immune System—ATF1—sarcoma	3.29e-05	0.000439	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KIT—sarcoma	3.21e-05	0.000429	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CREB1—sarcoma	3.06e-05	0.000409	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—FLT1—sarcoma	3.05e-05	0.000407	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PLCG1—sarcoma	2.99e-05	0.0004	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCR4—sarcoma	2.88e-05	0.000385	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFC—sarcoma	2.85e-05	0.000381	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ATF1—sarcoma	2.84e-05	0.00038	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IGF1R—sarcoma	2.84e-05	0.00038	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—TP53—sarcoma	2.71e-05	0.000363	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—FOXO1—sarcoma	2.71e-05	0.000362	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—IL2—sarcoma	2.71e-05	0.000362	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PDGFRB—sarcoma	2.7e-05	0.000361	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PDGFRA—sarcoma	2.66e-05	0.000356	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CREB1—sarcoma	2.61e-05	0.000349	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—MDM2—sarcoma	2.53e-05	0.000338	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL2—sarcoma	2.46e-05	0.000329	CbGpPWpGaD
Irbesartan—JUN—Immune System—FOXO1—sarcoma	2.46e-05	0.000328	CbGpPWpGaD
Irbesartan—JUN—Immune System—PDGFRB—sarcoma	2.45e-05	0.000328	CbGpPWpGaD
Irbesartan—JUN—Immune System—PDGFRA—sarcoma	2.41e-05	0.000322	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FLT1—sarcoma	2.28e-05	0.000304	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KDR—sarcoma	2.24e-05	0.000299	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PLCG1—sarcoma	2.24e-05	0.000299	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IGF1R—sarcoma	2.23e-05	0.000298	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ENO2—sarcoma	2.2e-05	0.000294	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—HBA1—sarcoma	2.19e-05	0.000292	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CTNNB1—sarcoma	2.18e-05	0.000292	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCR4—sarcoma	2.15e-05	0.000287	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ATF1—sarcoma	2.13e-05	0.000284	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—FOXO1—sarcoma	2.12e-05	0.000284	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—IL2—sarcoma	2.12e-05	0.000284	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PDGFRB—sarcoma	2.12e-05	0.000283	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PDGFRA—sarcoma	2.09e-05	0.000279	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KIT—sarcoma	2.06e-05	0.000276	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—NRAS—sarcoma	2.06e-05	0.000276	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—SRC—sarcoma	1.97e-05	0.000264	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CREB1—sarcoma	1.96e-05	0.000263	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL2—sarcoma	1.93e-05	0.000258	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—NRAS—sarcoma	1.9e-05	0.000254	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—EGFR—sarcoma	1.88e-05	0.000251	CbGpPWpGaD
Irbesartan—JUN—Immune System—KIT—sarcoma	1.87e-05	0.00025	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PLCG1—sarcoma	1.87e-05	0.00025	CbGpPWpGaD
Irbesartan—JUN—Immune System—CREB1—sarcoma	1.78e-05	0.000238	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—KRAS—sarcoma	1.78e-05	0.000237	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KDR—sarcoma	1.76e-05	0.000235	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EGFR—sarcoma	1.73e-05	0.000231	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IGF1R—sarcoma	1.67e-05	0.000223	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KRAS—sarcoma	1.63e-05	0.000218	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MDM2—sarcoma	1.62e-05	0.000217	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KIT—sarcoma	1.62e-05	0.000216	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—NRAS—sarcoma	1.62e-05	0.000216	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FOXO1—sarcoma	1.59e-05	0.000212	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PDGFRB—sarcoma	1.58e-05	0.000212	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PDGFRA—sarcoma	1.56e-05	0.000209	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CREB1—sarcoma	1.54e-05	0.000206	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—HRAS—sarcoma	1.51e-05	0.000202	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—EGFR—sarcoma	1.48e-05	0.000197	CbGpPWpGaD
Irbesartan—JUN—Immune System—MDM2—sarcoma	1.47e-05	0.000197	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL2—sarcoma	1.45e-05	0.000194	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ENO2—sarcoma	1.42e-05	0.00019	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCND1—sarcoma	1.42e-05	0.000189	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HBA1—sarcoma	1.41e-05	0.000189	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—JUN—sarcoma	1.41e-05	0.000189	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CTNNB1—sarcoma	1.4e-05	0.000187	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—KRAS—sarcoma	1.39e-05	0.000186	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HRAS—sarcoma	1.39e-05	0.000186	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL2—sarcoma	1.32e-05	0.000176	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KDR—sarcoma	1.31e-05	0.000176	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MDM2—sarcoma	1.28e-05	0.00017	CbGpPWpGaD
Irbesartan—JUN—Immune System—CTNNB1—sarcoma	1.27e-05	0.00017	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SRC—sarcoma	1.27e-05	0.000169	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—sarcoma	1.23e-05	0.000165	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NRAS—sarcoma	1.22e-05	0.000163	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KIT—sarcoma	1.21e-05	0.000162	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PLCG1—sarcoma	1.21e-05	0.000161	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HRAS—sarcoma	1.18e-05	0.000158	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ENO2—sarcoma	1.17e-05	0.000156	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HBA1—sarcoma	1.16e-05	0.000155	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ENO2—sarcoma	1.16e-05	0.000155	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CREB1—sarcoma	1.15e-05	0.000154	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HBA1—sarcoma	1.15e-05	0.000154	CbGpPWpGaD
Irbesartan—JUN—Immune System—SRC—sarcoma	1.15e-05	0.000154	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL2—sarcoma	1.14e-05	0.000152	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MYC—sarcoma	1.14e-05	0.000152	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCND1—sarcoma	1.11e-05	0.000148	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—sarcoma	1.11e-05	0.000148	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—JUN—sarcoma	1.11e-05	0.000148	CbGpPWpGaD
Irbesartan—JUN—Immune System—NRAS—sarcoma	1.11e-05	0.000148	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CTNNB1—sarcoma	1.1e-05	0.000147	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KRAS—sarcoma	1.05e-05	0.00014	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—sarcoma	1.01e-05	0.000135	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SRC—sarcoma	9.94e-06	0.000133	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PLCG1—sarcoma	9.9e-06	0.000132	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ENO2—sarcoma	9.89e-06	0.000132	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HBA1—sarcoma	9.83e-06	0.000131	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PLCG1—sarcoma	9.82e-06	0.000131	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—sarcoma	9.68e-06	0.000129	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NRAS—sarcoma	9.56e-06	0.000128	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MDM2—sarcoma	9.53e-06	0.000127	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—sarcoma	9.51e-06	0.000127	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—sarcoma	9.32e-06	0.000125	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRAS—sarcoma	8.92e-06	0.000119	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MYC—sarcoma	8.91e-06	0.000119	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—sarcoma	8.71e-06	0.000116	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2—sarcoma	8.51e-06	0.000114	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PLCG1—sarcoma	8.39e-06	0.000112	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCND1—sarcoma	8.3e-06	0.000111	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—sarcoma	8.23e-06	0.00011	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CTNNB1—sarcoma	8.22e-06	0.00011	CbGpPWpGaD
Irbesartan—JUN—Immune System—HRAS—sarcoma	8.08e-06	0.000108	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ENO2—sarcoma	7.63e-06	0.000102	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HBA1—sarcoma	7.58e-06	0.000101	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SRC—sarcoma	7.43e-06	9.93e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—sarcoma	7.32e-06	9.78e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—sarcoma	7.23e-06	9.67e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NRAS—sarcoma	7.15e-06	9.55e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRAS—sarcoma	7e-06	9.35e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MYC—sarcoma	6.66e-06	8.9e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—sarcoma	6.51e-06	8.7e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PLCG1—sarcoma	6.48e-06	8.66e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—sarcoma	6.15e-06	8.22e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—sarcoma	5.47e-06	7.31e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRAS—sarcoma	5.23e-06	6.99e-05	CbGpPWpGaD
